Group 1: Company Overview - Xizang Qizheng Tibetan Medicine Co., Ltd. is a leading enterprise in the Tibetan medicine sector, focusing on the research, production, and sales of innovative Tibetan medicines, with 25 exclusive varieties and 141 drug approval numbers covering various medical fields [2][3]. - Tibetan medicine has a history of over 3,800 years, integrating elements from Indian, Arabic, Chinese, and Bon medicine, and is recognized for its comprehensive medical system and unique treatment methods [3][4]. Group 2: Product and Market Strategy - The company emphasizes patient care by providing a diverse product line, including 60 OTC varieties and 3 state-secret technology products, targeting multiple therapeutic areas such as orthopedics, neurology, and pediatrics [3][4]. - The market for external pain relief patches is expected to grow significantly due to aging populations and the increasing prevalence of chronic diseases, with the company confident in expanding its main product, the pain relief patch [5][6]. Group 3: Innovation and Development - The company is committed to modernizing Tibetan medicine through technological innovation, including the establishment of an intelligent manufacturing system and the integration of traditional medicine with modern technology [4][5]. - As of the end of 2024, the company holds 141 drug approval numbers and 156 patent technologies, including 129 invention patents, showcasing its commitment to research and development [4][5]. Group 4: Marketing and Sales Strategy - The company is enhancing its marketing capabilities across various channels, including hospitals, retail, and e-commerce, to strengthen its brand presence and expand market reach [6][7]. - A focus on academic and brand marketing is aimed at increasing the influence of the "Qizheng" brand and achieving comprehensive growth across all product lines [6][7]. Group 5: Future Development Goals - The company's mission is to promote health wisdom and create life value, with strategic goals to become the leader in external pain relief and the Tibetan medicine market [5][6]. - The employee stock ownership plan is designed to align with revenue growth and net profit targets, reflecting the company's commitment to sustainable development [6][7].

| 证券代码：002287 | 证券简称：奇正藏药 | 公告编号：2025-044 | | --- | --- | --- | | 债券代码：128133 | 债券简称：奇正转债 | | 西藏奇正藏药股份有限公司 关于 2025 年第二季度可转换公司债券转股情况的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： | 证券代码：002287 | 证券简称：奇正藏药 | | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 债券代码：128133 | 债券简称：奇正转债 | | | | | | | | | | | | 转股价格：19.39 | 元/股 | | | | | | | | | | | | 转股时间：2021 | 年 | 3 | 月 | 29 | 日至 | 2026 | 年 | 9 | 月 | 21 | 日 | 根据《深圳证券交易所股票上市规则》、《深圳证券交易所上市公司自律监管 指引第 15 号——可转 ...

| 证券代码：002287 | 证券简称：奇正藏药 | 公告编号：2025-043 | | --- | --- | --- | | 债券代码：128133 | 债券简称：奇正转债 | | 西藏奇正藏药股份有限公司 关于实施权益分派期间奇正转债暂停转股的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 1、债券代码：128133 债券简称：奇正转债 2、转股期限：2021 年 3 月 29 日至 2026 年 9 月 21 日 3、暂停转股日期：2025 年 7 月 1 日至 2024 年度权益分派股权登记日 4、恢复转股日期：2024 年度权益分派股权登记日后的第一个交易日 西藏奇正藏药股份有限公司（以下简称"公司"）于 2025 年 5 月 16 日召开 2024 年度股东会，审议通过了《2024 年度利润分配预案》，公司将于近日根据相 关规定实施 2024 年度权益分派。根据公司《公开发行可转换公司债券募集说明 书》中"转股价格的调整方式及计算公式"（详见附件）条款的规定，公司可转 换公司债券（债券简称：奇正转债；债券代码：128133）将于 2025 ...

Company Overview - Tibet Qizheng Tibetan Medicine Co., Ltd. focuses on the research, production, and sales of Tibetan medicine, with a strong competitive edge in the external pain relief patch market [3][4][12] - The company reported a revenue of 23.38 billion yuan in 2024, a year-on-year increase of 14.32%, and a total profit of 6.46 billion yuan, up 0.28% from the previous year [4][5][10] - The company maintains a high gross profit margin of 82.11% and has a strong cash flow, with net cash inflow from operating activities amounting to 4.57 billion yuan [4][5][10] Financial Health - As of the end of 2024, the company had cash and cash equivalents totaling 38.45 billion yuan, with total debt at 17.56 billion yuan, indicating a low debt burden [5][10] - The company's debt-to-asset ratio stands at 39.42%, and the cash-to-short-term debt ratio is 4.02 times, reflecting strong solvency [5][10] - The company has a stable credit rating of AA, with a stable outlook for its convertible bonds [3][4] Market Position - The company is recognized as a leading Tibetan medicine enterprise, with a high market share and brand recognition in the external pain relief patch segment [4][12] - The main product, the pain relief patch, accounts for a significant portion of the company's revenue, indicating a high dependency on a single product [4][5][12] - The company faces competition from similar products in the domestic market, which may impact its market position [5][12] Research and Development - The company invests in R&D, with 1.05 billion yuan allocated in 2024, representing 4.48% of its total revenue [12][15] - It has established a systematic R&D framework for Tibetan medicine, collaborating with top academic institutions [12][15] - The company is focused on developing innovative products and improving existing ones, with several products undergoing clinical trials [12][15] Industry Environment - The pharmaceutical industry in China is undergoing significant policy changes, which may impact pricing and market dynamics [11][12] - The demand for pharmaceuticals is expected to continue growing, supported by sustainable healthcare funding [11][12] - The company is positioned to benefit from the ongoing reforms aimed at promoting high-quality traditional medicine [12]

西藏奇正藏药股份有限公司 公开发行可转换公司债券 2025 年跟踪评级报告 . | | | www.lhratings.com 1 联合〔2025〕5165 号 联合资信评估股份有限公司通过对西藏奇正藏药股份有限公司 主体及其相关债券的信用状况进行跟踪分析和评估，确定维持西藏 奇正藏药股份有限公司主体长期信用等级为 AA，维持"奇正转债" 信用等级为 AA，评级展望为稳定。 特此公告 联合资信评估股份有限公司 评级总监： 二〇二五年六月二十四日 跟踪评级报告 | 2 声 明 三、本报告引用的资料主要由该公司或第三方相关主体提供，联合资信 履行了必要的尽职调查义务，但对引用资料的真实性、准确性和完整性不作 任何保证。联合资信合理采信其他专业机构出具的专业意见，但联合资信不 对专业机构出具的专业意见承担任何责任。 四、本次跟踪评级结果自本报告出具之日起至相应债券到期兑付日有 效；根据跟踪评级的结论，在有效期内评级结果有可能发生变化。联合资信 保留对评级结果予以调整、更新、终止与撤销的权利。 五、本报告所含评级结论和相关分析不构成任何投资或财务建议，并且 不应当被视为购买、出售或持有任何金融产品的推荐意见或保证。 ...

Group 1: Company Overview - Xizang Qizheng Tibetan Medicine Co., Ltd. is a leading enterprise in the Tibetan medicine sector, focusing on the research, production, and sales of innovative Tibetan medicines, with 25 exclusive varieties and 141 drug approval numbers covering various medical fields [2][3]. Group 2: Historical Significance and Cultural Heritage - Tibetan medicine has a history of over 3,800 years, integrating elements from Indian, Arabic, and Chinese medicine, and is recognized for its comprehensive medical system and unique treatment methods [3][4]. - The company emphasizes the preservation of Tibetan medicine culture through various initiatives, including establishing relationships with contemporary Tibetan medicine masters and supporting Tibetan medicine schools [4]. Group 3: Product Development and Innovation - The company has a diverse product line, including 60 OTC varieties and 3 state-secret technology products, focusing on pain relief and various therapeutic areas [3][5]. - The company is committed to modernizing Tibetan medicine by integrating advanced technology and research to enhance clinical efficacy and develop new products [3][4]. Group 4: Market Position and Financial Performance - Since its listing in 2009, the company has shown steady growth, with cumulative dividends exceeding 2.69 billion yuan [4]. - The company has been recognized as a national-level high-tech enterprise and has established 24 wholly-owned and holding subsidiaries [4]. Group 5: Future Development Strategy - The company aims to become the leader in external pain relief and Tibetan medicine markets through a dual-driven strategy focusing on product diversity and modernization [4][6]. - The company plans to enhance brand competitiveness and clinical value through refined management and academic marketing strategies [6][7].

Group 1 - The company, Tibet Qizheng Pharmaceutical Co., Ltd., has received notification from its controlling shareholder, Gansu Qizheng Industrial Group Co., Ltd., regarding the pledge of part of its shares [1] - The pledged shares amount to 7,100,000 shares, representing 1.95% of the total share capital [1] - As of the announcement date, the total number of pledged shares held by the shareholder and its concerted actors is 462,941,688 shares, accounting for 87.14% of their holdings [2] Group 2 - The company confirms that the pledged shares do not pose a risk of forced liquidation or transfer [2] - The company is committed to fulfilling its information disclosure obligations in accordance with relevant regulatory requirements [2]

西藏奇正藏药股份有限公司 | 证券代码：002287 | 证券简称：奇正藏药 | 公告编号：2025-042 | | --- | --- | --- | | 债券代码：128133 | 债券简称：奇正转债 | | 关于控股股东股份质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、股东股份质押基本情况 西藏奇正藏药股份有限公司（以下简称"公司"、"本公司"）近日接到控 股股东甘肃奇正实业集团有限公司（以下简称"奇正集团"）函告，获悉奇正集 团所持有本公司的部分股份被质押。奇正集团为公司控股股东，持有公司 364,546,473股，占公司总股本的68.62%。具体事项如下： 2、股东股份累计质押情况 截至公告披露日，上述股东及其一致行动人所持质押股份情况如下： 单位：股 | 股东 | 持股数量 | 持股 | 本次质押 | 本次质押后 | 占其 | 占公司 | 已质押股份情 | 未质押股份 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 名称 | | 比例 | 前质押股 | 质押股 ...

Fundraising Overview - The company has successfully issued convertible bonds with a total amount of RMB 800 million, with a net fundraising amount of RMB 790,500,216.96 after deducting issuance costs [1] - The funds raised are designated for the "Qizheng Tibetan Medicine Pharmaceutical Industrial Base Construction Project" [1] Fund Management and Usage - The company has established a special account for the management and usage of the raised funds, in compliance with relevant regulations and internal management methods [1] - A tripartite supervision agreement has been signed with the bank and the sponsor to clarify the rights and obligations of all parties involved [1] Project Status - The "Qizheng Tibetan Medicine Pharmaceutical Industrial Base Construction Project" has reached a state of readiness for use and has been completed [4] - The company retains the special account for the project to manage any remaining payments, with any excess costs covered by self-raised funds [4] Account Closure - The special account for the raised funds has been closed following the completion of the project, and the corresponding supervision agreement has also been terminated [4]

| 证券代码：002287 | 证券简称：奇正藏药 | 公告编号：2025-041 | | --- | --- | --- | | 债券代码：128133 | 债券简称：奇正转债 | | 西藏奇正藏药股份有限公司 关于子公司注销募集资金专项账户的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、募集资金基本情况 经中国证监会《关于核准西藏奇正藏药股份有限公司公开发行可转换公司债 券的批复》（证监许可【2020】1766号）核准，西藏奇正藏药股份有限公司（以 下简称"公司"）公开发行可转换公司债券，每张面值为人民币100元，共计800 万张，按面值发行。本次发行可转换公司债券募集资金总额为人民币 800,000,000.00元，募集资金在扣除需支付的承销及保荐费、律师费、审计验资 费、资信评级费、评估费及信息披露费用等其他发行费用后，实际募集资金净额 为790,500,216.96元。中勤万信会计师事务所（特殊普通合伙）出具勤信验字 【2020】第0055号《验资报告》。募集资金到账后，公司已对募集资金进行了专 户存储。 2、募投项目建设情况 募投项目" ...